Table 2.
Therapy | n (%) |
---|---|
Anti-infective agents | |
Oseltamivir | 3 (4) |
Antibacterial | 71 (95) |
Antimalarial | 4 (5) |
Antifungal | 12 (16) |
Antithrombotic agents | |
Initial dosing | |
Thromboprophylaxis | 52 (69) |
Intermediate | 3 (4) |
Therapeutic anticoagulation | 20 (27) |
Maximal dosing | |
Thromboprophylaxis | 31 (41) |
Intermediate | 1 (1) |
Therapeutic anticoagulation | 43 (57) |
Reason for anticoagulation | |
Empirical | 5 (12) |
Cardiac indication | 16 (37) |
VTE | 14 (33) |
CRRT / ECMO | 4 (9) |
Antiplatelet therapy use | 20 (27) |
Immunomodulating agents | |
Corticosteroids | 35 (47) |
Other | 0 (0) |
Non-pharmacological | |
Invasive mechanical ventilation | 42 (56) |
Non-invasive positive-pressure ventilation | 16 (21) |
High-flow nasal cannula | 2 (3) |
Extracorporeal membrane oxygenation | 1 (1) |
Continuous renal replacement therapy | 7 (9) |
IMV-specific support | |
NMB: bolus only | 6/43 (14) |
NMB: continuous infusion | 16/43 (37) |
Nitric oxide | 15/43 (35) |
Prone position | 11/43 (26) |
Percutaneous tracheostomy | 10/43 (23) |
CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane oxygenation; NMB = neuromuscular blockers; VTE = venous thromboembolism, IMV = invasive mechanical ventilation